AbbVie unit wins $56 mln in US patent trial against Botox rival
A Delaware federal jury ruled that Revance Therapeutics must pay AbbVie’s Allergan $56 million for patent infringement related to its anti-wrinkle drug Daxxify, which was found to mimic Allergan’s Botox manufacturing process. Allergan, which generated over $4.4 billion from Botox sales in the U.S. last year, sued Revance in 2021. Revance denied the allegations, claiming the patents were invalid. The case is Allergan Inc v. Revance Therapeutics Inc, U.S. District Court for the District of Delaware.
By Blake Brittain
July 21 (Reuters) - A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie’s (ABBV.N) Allergan Inc $56 million after finding that Revance’s anti-wrinkle medication Daxxify infringed patents covering Allergan’s rival drug Botox.
The jury agreed with Allergan that Revance’s manufacturing process for Daxxify mimics Allergan’s technology for making Botox.
Spokespeople for Revance and Allergan did not immediately respond to requests for comment on the verdict on Monday.
Ireland-based Allergan sued Revance in 2021 for allegedly infringing patents related to harnessing and producing botulinum toxins used in anti-wrinkle injections like Botox and Daxxify. Revance denied the allegations and argued that the patents were invalid.
Allergan earned more than $4.4 billion in revenue from U.S. sales of Botox last year, according to a company report. Nashville, Tennessee-based Revance said in a company report last year that it had earned more than $79 million from sales of Daxxify in the first nine months of 2024.
Privately owned Crown Laboratories agreed to buy Revance last August.
The case is Allergan Inc v. Revance Therapeutics Inc, U.S. District Court for the District of Delaware, No. 1:21-cv-01411.
For Allergan: Eric Dittmann, Melanie Rupert, Isaac Ashkenazi, Ashley Mays-Williams and Chad Peterman of Paul Hastings
For Revance: Dennies Varughese, Adam LaRock, Byron Pickard, Nirav Desai and Deirdre Wells of Sterne Kessler Goldstein & Fox
